NCT03913000View on ClinicalTrials.gov

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 29, 2019

Primary Completion Date

August 22, 2019

Study Completion Date

August 22, 2019

Conditions
Renal Impairment
Interventions
DRUG

ID-085

Hard capsules for oral administration formulated at a strength of 200 mg

Trial Locations (1)

24105

CRS Clinical Research Services Kiel GmbH, Kiel

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY